These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27185425)

  • 1. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
    Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
    J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
    Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
    Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of lenalidomide in refractory lupus pernio.
    Dalm VA; van Hagen PM
    JAMA Dermatol; 2013 Apr; 149(4):493-4. PubMed ID: 23715134
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
    Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
    Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
    Nutan F; Ortega-Loayza AG
    J Investig Dermatol Symp Proc; 2017 Oct; 18(2):S64-S68. PubMed ID: 28941497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
    Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
    Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thalidomide therapy of cutaneous lupus erythematosus].
    Bohmeyer J; Achenbach A; Westenberger M; Stadler R
    Hautarzt; 2002 Nov; 53(11):744-8. PubMed ID: 12402138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
    Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
    J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions.
    Nahmias Z; Nambudiri VE; Vleugels RA
    J Am Acad Dermatol; 2016 Jul; 75(1):210-2. PubMed ID: 27317516
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients.
    Aitmehdi R; Arnaud L; Francès C; Senet P; Monfort JB; de Risi-Pugliese T; Barbaud A; Cohen-Aubart F; Haroche J; Pha M; Hie M; Le Guern V; Costedoat-Chalumeau N; Mékinian A; Fain O; Mathian A; Amoura Z; Chasset F
    J Am Acad Dermatol; 2021 Apr; 84(4):1171-1174. PubMed ID: 33221461
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
    Okon L; Rosenbach M; Krathen M; Rose M; Propert K; Okawa J; Werth V
    J Am Acad Dermatol; 2014 Mar; 70(3):583-4. PubMed ID: 24528907
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of lenalidomide in treating refractory prurigo nodularis.
    Liu H; Gaspari AA; Schleichert R
    J Drugs Dermatol; 2013 Mar; 12(3):360-1. PubMed ID: 23545923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.
    Stevens RJ; Andujar C; Edwards CJ; Ames PR; Barwick AR; Khamashta MA; Hughes GR
    Br J Rheumatol; 1997 Mar; 36(3):353-9. PubMed ID: 9133968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide.
    Atra E; Sato EI
    Clin Exp Rheumatol; 1993; 11(5):487-93. PubMed ID: 8275583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 17. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
    Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
    J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
    Baret I; De Haes P
    J Dermatolog Treat; 2015 Apr; 26(2):173-7. PubMed ID: 24731053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
    Wang X; Li M; Zeng X; Wang Q
    Rheumatology (Oxford); 2023 Oct; 62(10):e293-e294. PubMed ID: 36943383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.